ASX ANNOUNCEMENT

Lumos Diagnostics Quarterly Activity Statement and Cash Flow Report

Key Highlights from the Third Quarter of Financial Year 2026

- **FebriDx® –** US FDA Grants 510(k) with CLIA waiver for FebriDx® - expanding addressable market to approx. 80 million patients, per annum[1] and allowing for use at over 300,000 US locations[2]
- **FebriDx® CLIA waiver milestone payments** – Successful 510(k) with CLIA waiver application triggers key milestone payments of US$5.0 million from PHASE Scientific and US$0.5 million from BARDA
- **FebriDx® Paediatric study milestone payment** – completed milestone tied to total number of enrolled patients to-date in its BARDA-funded paediatric clinical study, triggering a milestone payment of US$0.72 million
- **Hologic fFN project continues** with Phase 2, including the additional scope of works in progress
- **Successful Placement completed; SPP Offer launched:** A$20.0 million placement completed with participation from existing and new institutional and sophisticated investors; SPP launched on identical terms with one free attaching option for every two shares subscribed for. SPP closes 24 April 2026
- **Revenue of US$4.8 million for the quarter,** up 37% over the pcp, with Q3 Product revenue of US$2.4 million and Services revenue US$2.4 million
- **Operating cash outflow** for Q3 was US$2.8 million with investments in inventory production
- **Cash balance of US$1.1 million** at 31 March 2026. In April, Lumos strengthened its balance sheet with receipt of US$5.0 million milestone payment from PHASE Scientific, and the Placement proceeds of A$20.0 million (before costs)

All amounts are in USD, the Company's reporting currency, unless otherwise stated.

MELBOURNE, Australia (20 April 2026) – Lumos Diagnostics (ASX: LDX), ("Lumos" or the "Company") a leader in rapid point-of-care diagnostic technologies, is pleased to release its Quarterly Activity Statement and Appendix 4C Quarterly Cash Flow Report for the third quarter of FY26 (Q3 FY26 / the three months ended 31 March 2026).

[1] Precision Business Insights, US Acute Respiratory Infections, 2024
[2] Division of Clinical Laboratory Improvement and Quality Centers for Medicare & Medicaid services, March 2024 (CMS CLIA Database)

Operational Update

Revenue Summary:

US$M	Quarter 3			Year to date (9 months)		
	FY26	FY25	Mv't	FY26	FY25	Mv't
Products	2.4	0.7	+243%	4.1	1.6	+156%
Services	2.4	2.8	-14%	6.8	8.2	-17%
Total	**4.8**	**3.5**	**+37%**	**10.9**	**9.8**	**+11%**

Lumos recorded unaudited revenue of US$4.8 million for the quarter ended 31 March 2026, up 37% on the pcp, and up 78% on the previous quarter.

Revenue from the Products business during the quarter was US$2.4 million, versus US$0.7 million in Q3 FY25. Growth was driven primarily from FebriDx® sales, which represented the majority of sales during the period, more than offsetting the discontinuation of Lumos' proprietary ViraDx® test.

Revenue generated during the quarter from the Services business was US$2.4 million, down 14% on the pcp. Work continued on 12 projects for customers during the quarter, generating growth in consulting revenue of 22%, however total Services revenue was impacted by the lower amortization rate on the Hologic IP license fee (US$0.3 million recognized in Q3 FY26 v's US$1.1 million in Q3 FY25), as a result of Hologic's extension of the fFN project timeline.

Products Division

We provide a summary of the following product updates below.

FebriDx®

FebriDx® is Lumos' unique, rapid point of care test that helps clinicians differentiate between bacterial and non-bacterial acute respiratory infections through a simple fingerstick blood sample after 10 minutes. To date, Lumos has received regulatory registrations for the use of FebriDx® in the U.S., UK, Europe, Kuwait, UAE and Australia.

On 27 March 2026, Lumos announced that the US FDA had granted a new 510(k) clearance [K260787] with associated Clinical Laboratory Improvement Amendments (CLIA) waiver for FebriDx®.

A transformative moment for the Company, the CLIA waiver expands the applicability of FebriDx® to over 80 million US patients per annum, and a total market opportunity of US$1.0+ billion, representing a 15-fold increase on the market opportunity prior to CLIA waiver[3,4].

[3] Division of Clinical Laboratory Improvement and Quality Centers for Medicare & Medicaid services, March 2024 (CMS CLIA Database).
[4] Precision Business Insights, US Acute Respiratory Infections, 2024

Lumos has an exclusive distribution agreement for the US market for FebriDx® with PHASE Scientific valued at US$317 million over 6 years (ASX: 16 July 2025). Under this agreement, the granting of CLIA waiver triggered a milestone payment for future product orders of US$5.0 million from PHASE Scientific which was paid post quarter (ASX: 14 April 2026). Lumos will also shortly receive a US$507,377 milestone payment under its contract with BARDA following the granting of the CLIA waiver. These combined receipts will further strengthen Lumos' balance sheet and provide additional funding to support the broader US commercial rollout of FebriDx®.

CLIA waived status expands the applicability of FebriDx® to over 300,000 locations across the US[1,5], covering a broad range of healthcare settings, spanning primary care physician offices, urgent care clinics, retail health & pharmacy clinics and community health centres that hold a Certificate of Waiver. This milestone marks a significant commercial achievement for Lumos, positioning FebriDx® to reach tens of millions more patients without the need for complex laboratory infrastructure or specialised training.

This expanded opportunity aligns with Lumos' US commercial strategy, which includes support from the Company's partnerships with PRO-spectus, AcuityMD and PHASE Scientific. The focus remains on driving broader market adoption through healthcare provider education, integration into outpatient clinic workflows, and securing reimbursement from private payors.

Following the granting of CLIA waiver, Lumos' exclusive US distributor, PHASE Scientific, lodged a purchase order valued at US$1.3 million on 30 March 2026, and this product has been shipped and revenue included in the Q3 results. This represents Lumos' largest FebriDx® order to date and was applied to the US$2.5 million pre-payments received for prior milestones, namely the execution of the Lumos-PHASE agreement and submission of the CLIA waiver application to the US FDA.

Furthermore, on 14 April 2026, Lumos received confirmation that WellStreet Urgent Care will expand its FebriDx® program from a single initial site to a further 43 locations across its network. This follows the agreement announced on 16 October 2025 to advance testing and reimbursement pathways through WellStreet's joint venture with Piedmont Healthcare in Atlanta, where the initial site has been managing approximately 50 patients per day presenting with acute respiratory infections.

Building on the success of this pilot and supported by FebriDx achieving CLIA waived status, the program will now be rolled out over the next two months across additional sites in the Fayetteville District, a second Georgia district, and the entire Michigan market. Subject to the success of this phase, Lumos expects a broader rollout across WellStreet's remaining 119 urgent care locations over the following 6–12 months.

CLIA waived paediatric study commences: On 1 September 2025, BARDA exercised its option to support Lumos in conducting a clinical study and regulatory submission aimed at expanding the age eligibility for FebriDx® use to include children 2 to 12 years of age in CLIA waived settings ("paediatric study"). The study will be conducted across approximately 20 clinical sites in the US, and is expected to run for around 12 months, following which a formal submission will be prepared for the FDA.

[5] Division of Clinical Laboratory Improvement and Quality Centers for Medicare & Medicaid services, March 2024 (CMS CLIA Database).

Milestone payments from BARDA to Lumos of US$6.2 million will be triggered upon the achievement of twelve milestone events, including clinical trial set-up, patient recruitment, FDA application submission, and FDA granting of 510(k) clearance and CLIA waiver categorization for children 2 – 12 years of age.

On 23 February 2026, Lumos announced it had completed an enrollment milestone (Milestone #6) in the clinical study, triggering a US$720,000 milestone payment under the Company's contract with BARDA. Together with the previously achieved milestones, Lumos has now generated a total of US$1,920,000 in non-dilutive milestone payments for the paediatric study to date.

Development Services and Contract Manufacturing Division

Lumos generates revenue from the provision of point of care diagnostic test and custom reader development services, contract manufacturing and IP license revenue. Development services included ongoing work on 12 projects during the quarter, including projects for Hologic, Micro-Pak, TeleMedVet and Aptatek Biosciences.

Hologic -fFN Diagnostic Product

On 11 January 2024, Lumos announced an IP licensing agreement (worth US$10.0 million, with payment received in FY24) and a Development Agreement (initially worth US$4.7 million) with Hologic, a leading global women's health provider, to develop the next generation of Hologic's on market fFN diagnostic product for pre-term birth, for which Hologic is the only global manufacturer. A key focus of the development program is to adapt the test for use on the Lumos proprietary reader platform and provide improved connectivity options.

The development project has since been expanded by five additional scopes of work (SOW):

1. March 2025 for between US$0.6 - US$0.8 million (relating to the delivery of the system prototype in Phase 3)
2. August 2025 for between US$0.7 - US$0.9 million (relating to the assay feasibility work in Phase 2)
3. November 2025 for between US$0.5 - US$0.6 million (relating to assay feasibility work in Phase 2)
4. February 2026 for US$0.2 million (related to hardware work in Phase 3); and
5. March 2026 for US$0.3 million (relating to software work in Phase 3).

In addition, the payment schedule for the project, as allocated across the three phases, was amended in July 2025. This new payment schedule is outlined below.

Including the five additional SOW's, the body of work under the Development Agreement is being conducted across three phases (which include nine original milestones), providing total milestone payments of between US$6.9 - US$7.6 million, structured as follows:

- Phase 1 (milestone 1) - Product Definition and Planning: define the parameters for the product and establish a project plan - US$0.4 million – this phase has been completed, and payment has been received;
- Phase 2 (milestones 2 and 3) - Assay Feasibility: conduct work to demonstrate the assay can detect the biomarkers - US$3.0 to US$3.3 million – work on the first milestone of this phase has been

completed. Work on the second and final milestone for this phase, including the two additional SOW's is expected to be completed by the end of May 2026. For this phase, payments of US$2.8 million have been received to-date.

- Phase 3 (milestones 4 to 9) - System Prototype Delivery: deliver a working prototype of the system – US$3.5 - US$3.9 million – milestone 4 and 5 of this phase are in progress, including the additional three SOW's. Whilst Lumos completes the additional SOW's on assay feasibility, work on these phase 3 milestones is likely to be delayed, so the estimated timeline for the project has been pushed out to February 2027. For this phase, payments of US$1.0 million have been received to-date.

Aptatek Biosciences – PheCheck in-home monitoring for PKU

On 1 September 2025, Lumos secured a follow-on development contract with New Jersey-based Aptatek Biosciences. (Aptatek) to advance the PheCheck™ aptamer-based, in-home monitoring tool for the screening and management of phenylketonuria (PKU).

Under the new contract, Lumos will focus on maturing the design of the tests, blood processing unit, and readers; conducting formal verification testing to ensure the device meets product requirements for clinical trials and U.S. Food and Drug Administration (FDA) submission.

The contract, valued at approximately US$1.5 million and charged on a time-and-materials basis, has commenced and will run for around 10 months.

On 19 January 2026, the contract was extended to include the management of an IRB approved multi-center study to advance the PKU in-home monitoring device to progress to FDA submission. The contract is valued at approximately US$0.4 million, commencing January 2026 and is expected to run for around 12 months.

This work will be undertaken by the same experienced clinical affairs team responsible for the successful execution of Lumos's FebriDx® clinical trials, including the FebriDx® CLIA waiver program.

Subject to the successful study and achievement of FDA clearance, Lumos expects to pursue additional revenue opportunities with Aptatek, including PheCheck™ test and reader manufacturing.

Micro-Pak follow-on contract

Following quarter end, on 8 April 2026, Lumos announced that it had secured a supply contract to manufacture Micro-Pak's Mold Analyzer system, a solution designed to enable rapid, on-site detection of mold for both professional and consumer use, significantly reducing turnaround times compared to traditional lab-based analysis.

Developed by Lumos for Micro-Pak, the system comprises a novel mold detection test, a Lumos digital camera reader, and a custom mobile application. The agreement represents a follow-on contract for Lumos' Commercial Services Division, covering the production of custom readers and point-of-care tests, with an initial purchase order of US$250,000 received under the three-year manufacturing arrangement.

Summary of Cash Receipts and Outflows

Lumos generated cash receipts from customers of US$2.2 million for the quarter ended 31 March 2026, compared to US$1.5 million receipts from customers in the pcp.

Cash operating expenses for Q3 FY26 were US$5.6 million, an increase of US$1.9 million over Q3 FY25 expenses of $3.7 million. This was primarily due to growth in the business, increased spending on inventory, additional consulting service delivery costs and the costs of the FebriDx paediatric trial.

During the quarter cash receipts of US$0.7 million were received from government grants, with all of this relating to payments from BARDA for the paediatric trial.

In total, the net operating cash outflow for Q3 FY26 was US$2.8 million, up from an outflow of US$1.3 million in the pcp, mainly due to lower receipts from customers, as the pre-payments from PHASE Scientific were made in Q1 FY26, with product being shipped in Q2 and Q3 FY26.

As in prior quarters, there continued to be minimal capital expenditure during Q3 FY26.

During the period, the Company received US$0.5 million from the exercise of options.

A drawdown of US$0.7 million (A$1.0 million) relating to the loan facility from Tenmile and Ryder Capital was made on 20 January 2026 to meet working capital requirements. It is planned that this loan be repaid from the proceeds of the recent capital raise.

After including investing activities and lease payment expenses, net cash outflow for the quarter totaled US$3.1 million, bringing the closing cash balance at the end of the quarter, Q3 FY26, to US$1.1 million.

Post Reporting Date

The granting of the 510(k) and associated CLIA waiver clearance for FebriDx® by the US FDA (ASX: 27 March 2026), was confirmed to satisfy the milestone under the agreement triggering a payment by PHASE to Lumos of US$5.0 million. This payment was received on 14 April 2026.

The funds associated with the Company's placement of A$20.0 million (before costs) to institutional and sophisticated investors (ASX: 27 March 2026) were received on 8 April 2026.

The Company also expects to receive the US$507,377 milestone payment associated with the 510(k) and associated CLIA waiver from BARDA in the coming weeks.

Share Purchase Plan Offer – Closing 24 April 2026

The Company is completing a Share Purchase Plan (SPP) offer that runs from 10 – 24 April 2026. The SPP gives eligible shareholders the opportunity to buy additional shares in the Company on the same terms as provided to institutional investors under the recent placement. Under the SPP, shareholders can apply for up to A$30,000 worth of shares at an issue price of A$0.225 per share. For every two shares subscribed for, participants will also receive one free-attaching unquoted option, exercisable at A$0.34 per option and expiring on 31 December 2027. The offer is available to shareholders who were registered as holding shares

at 7:00pm (AEDT) on 26 March 2026, with addresses in Australia or New Zealand, and is subject to the terms and conditions outlined in the Prospectus released on 10 April 2026.

Payments to Related Entities

In accordance with Listing Rule 4.7C.3 and as outlined in Section 6.1 of Appendix 4C, the Company discloses payments to related entities of US$229,000, comprising directors' fees, consulting fees, salary & wages and superannuation.

Key Priorities

The key focus areas for Lumos are currently summarized as follows:

- Continuing to drive sales of FebriDx in the US, by implementing the agreement with PHASE Scientific, drive market awareness, usage uptake, reimbursement coverage, and manufacturing scale-up.
- Progress the BARDA FebriDx paediatric study – to address an important clinical market for the 2-12 age group which will expand the U.S. market for FebriDx® by an additional 15% - 20%.
- Deliver on the Hologic fFN development milestones – remaining assay feasibility work from Phase 2 and the Phase 3 milestones, resulting in approximately US$3.4 million in additional non-dilutive milestone payments.

In closing, CEO Doug Ward said: *"Closing out this quarter with a new 510(k) clearance with attached CLIA waiver for FebriDx® marks a defining moment for Lumos. These achievements are the direct result of the skill, focus and determination our team brings to delivering high quality, care changing solutions.*

I want to extend my sincere thanks to the patients who participated in the clinical studies that supported these approvals, as well as to BARDA for their continued support. I also want to acknowledge our partners who are working closely with us to drive FebriDx® uptake across the US healthcare system.

And to our shareholders - thank you for your support through the recent A$20 million placement and in considering the current SPP. Your commitment is critical in positioning Lumos for the growth opportunities ahead."

Webinar Invitation

The Company invites investors and analysts to attend its Q3 FY26 results webinar, to be held online on Tuesday, 21 April 2026 at 11:00am (AEST.)

Participants can register ahead of time, via the following link:
https://us02web.zoom.us/webinar/register/WN_LGuVX42cSH6Fq0asH0O5uw

Once the registration form is complete, investors will receive a confirmation email with details on how to access the meeting. The Lumos team looks forward to welcoming all those who are able to attend.

-Ends-

This announcement has been approved by the Lumos Disclosure Committee.

About Lumos Diagnostics

Lumos Diagnostics specializes in rapid and complete point-of-care diagnostic test technology to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customized assay development and manufacturing services for point-of-care tests and proprietary digital reader platforms. Lumos also directly develops, manufactures, and commercializes novel Lumos-branded point-of-care tests that target infectious and inflammatory diseases.

For more information visit lumosdiagnostics.com.

Forward-Looking Statements

This announcement contains forward-looking statements, including references to forecasts. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions, and other important factors, many of which are beyond Lumos' control and speak only as of the date of this announcement. Readers are cautioned not to place undue reliance on forward-looking statements.

Media Contact:	**Investor Contact:**	**Company Registered Office:**
Tom Trezona – Australia H^CK Acting Managing Director tom@hck.digital +61 411 235 692	George Kopsiaftis IR Specialist, IR Department ir@lumosdiagnostics.com +61 409 392 687	Lumos Diagnostics Holdings Ltd Suite 2, Level 11 385 Bourke Street Melbourne VIC 3000 info@lumosdiagnostics.com +61 3 9087 1598

Appendix 4C

Quarterly Cash Flow report for entities subject to Listing Rule 4.7B

Name of entity

Lumos Diagnostics Holding Limited

ABN	**Quarter ended ("current quarter")**
66 630 476 970	31 March 2026

Consolidated statement of cash flows		**Current quarter US$'000**	**Year to date (9 months) US$'000**
1.	**Cash flows from operating activities**		
1.1	Receipts from customers	2,208	10,863
1.2	Payments for		
	(a) service delivery, research and development	(1,064)	(3,175)
	(b) product manufacturing and operating costs	(1,634)	(3,184)
	(c) sales, advertising and marketing	(410)	(1,127)
	(d) medical affairs and clinical trial costs	(510)	(2,169)
	(e) leased assets	-	-
	(f) staff costs*	(1,231)	(4,249)
	(g) administration and corporate costs	(716)	(2,024)
1.3	Dividends received (see note 3)	-	-
1.4	Interest received	2	11
1.5	Interest and other costs of finance paid	(140)	(422)
1.6	Income taxes paid	-	-
1.7	Government grants and tax incentives	720	3,472
1.8	Other (provide details if material)	-	-
1.9	**Net cash from / (used in) operating activities**	**(2,775)**	**(2,004)**

*Staff costs have been allocated to their respective departments above.

2.	**Cash flows from investing activities**		
2.1	Payments to acquire or for:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	(46)	(232)
	(d) investments	-	-

Consolidated statement of cash flows		Current quarter US$'000	Year to date (9 months) US$'000
	(e) intellectual property	-	-
	(f) other non-current assets (including capitalised product development costs)	-	-
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
2.6	**Net cash from / (used in) investing activities**	**(46)**	**(232)**

3.	**Cash flows from financing activities**		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	-	-
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	498	1,466
3.4	Transaction costs related to issues of equity securities or convertible debt securities	-	-
3.5	Proceeds from borrowings	686	686
3.6	Repayment of borrowings	-	-
3.7	Transaction costs related to loans and borrowings	(13)	(13)
3.8	Dividends paid	-	-
3.9	Other:		
	Lease payments (principal component)	(259)	(774)
3.10	**Net cash from / (used in) financing activities**	**912**	**1,365**

Consolidated statement of cash flows		Current quarter US$'000	Year to date (9 months) US$'000
4.	**Net increase / (decrease) in cash and cash equivalents for the period**		
4.1	Cash and cash equivalents at beginning of period	2,994	1,956
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(2,775)	(2,004)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(46)	(232)
4.4	Net cash from / (used in) financing activities (item 3.10 above)	912	1,365
4.5	Effect of movement in exchange rates on cash held	47	47
4.6	**Cash and cash equivalents at end of period**	**1,132**	**1,132**

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter US$'000	Previous quarter US$'000
5.1	Bank balances	1,132	2,994
5.2	Call deposits	-	-
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	**Cash and cash equivalents at end of quarter (should equal item 4.6 above)**	**1,132**	**2,994**

6.	Payments to related parties of the entity and their associates	Current quarter US$'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	229
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-

Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.

7.	**Financing facilities** *Note: the term "facility' includes all forms of financing arrangements available to the entity.* *Add notes as necessary for an understanding of the sources of finance available to the entity.*	**Total facility amount at quarter end US$'000**	**Amount drawn at quarter end US$'000**
7.1	Loan facilities	2,743	-
7.2	Credit standby arrangements	-	-
7.3	Other (please specify)	-	-
7.4	**Total financing facilities**	2,743	-

7.5	**Unused financing facilities available at quarter end**	2,743

7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.

Item 7.1 includes a loan facility balance of A$4.0 million with major shareholders Tenmile Ventures Pty Ltd and Ryder Capital Management Pty Ltd.

A drawdown under the facility of A$1.0 million was made on 20 February 2026 with the interest rate on drawn amounts being 15.0% per annum.

Maturity date is 12 months from the first drawdown date.

The amount shown above is for the balance of the loan facility of A$4.0 million at an FX rate of A$1.00:US$0.6857.

Refer to the ASX announcements for further details on this loan facility.

8.	**Estimated cash available for future operating activities**	**US$'000**
8.1	Net cash from / (used in) operating activities (item 1.9)	(2,775)
8.2	Cash and cash equivalents at quarter end (item 4.6)	1,132
8.3	Unused finance facilities available at quarter end (item 7.5)	2,743
8.4	Total available funding (item 8.2 + item 8.3)	3,875
8.5	**Estimated quarters of funding available (item 8.4 divided by item 8.1)**	1.4x

Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.

8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:

8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?

Answer: Net operating cash flows for the fourth quarter are expected to be improved, with a pre-payment of US$5.0 million received from the Company's distributor for FebriDx in the US, Phase Scientific. This milestone payment became due on 27 March 2026 upon the 510k and CLIA waiver clearance for FebriDx by the US FDA. Refer to ASX announcement dated 27 March 2026. The payment of US$5.0 million was received on 14 April 2026.

8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?

Answer: Yes. The Company completed a placement of A$20.0 million (before costs) to institutional and sophisticated investors which was announced on 27 March 2026. These funds were received on 8 April 2026. In addition, the Company is completing a Share Purchase Plan that runs from 10 – 24 April 2026.

8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

Answer: Yes. On the basis of the capital raise completed and improved net operating cash flow.

Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.

Compliance statement

1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.

2 This statement gives a true and fair view of the matters disclosed.

Date: **20 April 2026**

Authorised by: **The Lumos Disclosure Committee**
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.

2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.

3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.

4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [*name of board committee – eg Audit and Risk Committee*]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".

5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.